Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37163206)

  • 1. HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.
    Desai O; Wang R
    Oncotarget; 2023 May; 14():439-443. PubMed ID: 37163206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma.
    Rathore M; Zhang W; Wright M; Zarei M; Vaziri-Gohar A; Hajihassani O; Abbas A; Feng H; Brody J; Markowitz SD; Winter J; Wang R
    J Cancer Sci Clin Ther; 2022; 6(4):431-445. PubMed ID: 36644317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomic landscape of endothelial cells: Key tumor microenvironment components indicating variable clinical outcomes in pancreatic ductal adenocarcinoma.
    Xie P; Tan SY; Li HF; Tang HD; Zhou JH
    Environ Toxicol; 2024 Feb; 39(2):572-582. PubMed ID: 37449672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
    Brown M; Zhang W; Yan D; Kenath R; Le L; Wang H; Delitto D; Ostrov D; Robertson K; Liu C; Pham K
    PLoS One; 2020; 15(1):e0226917. PubMed ID: 31929540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer stem cells: A state or an entity?
    Hermann PC; Sainz B
    Semin Cancer Biol; 2018 Dec; 53():223-231. PubMed ID: 30130664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
    Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
    Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
    Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
    Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
    J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of pancreatic cancer therapy resistance by chemokines.
    Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia and pancreatic ductal adenocarcinoma.
    Yamasaki A; Yanai K; Onishi H
    Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.
    Coppola S; Carnevale I; Danen EHJ; Peters GJ; Schmidt T; Assaraf YG; Giovannetti E
    Drug Resist Updat; 2017 Mar; 31():43-51. PubMed ID: 28867243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
    Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
    Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8.
    Chen SJ; Lian GD; Li JJ; Zhang QB; Zeng LJ; Yang KG; Huang CM; Li YQ; Chen YT; Huang KH
    Cancer Med; 2018 Nov; 7(11):5679-5690. PubMed ID: 30311406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
    Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
    Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.